Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026)

SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today highlighted updated clinical, safety and translational data for AlloNK® (also known as AB-101) in combination with rituximab, presented by Guillermo J. Valenzuela, M.D., F.A.C.R., medical director of Integral Rheumatology & Immunology Specialists, in an oral session at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026) in Paris.